Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model

Author： Kreck Simon   Klaus Jochen  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.4, 2008-01, pp. : 311-328

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Treatments for Inflammatory Bowel Disease

By Bodger Keith  

PharmacoEconomics, Vol. 29, Iss. 5, 2011-05 ,pp. : 387-401

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Alendronate (Fosamax ® ) for the Treatment of Osteoporosis and Prevention of Fractures

By Johnell O.  

PharmacoEconomics, Vol. 21, Iss. 5, 2003-01 ,pp. : 305-314

Adis International

Access to resources Recommend Favorite

Cost-Utility of Treatments for Pulmonary Arterial Hypertension: A Markov State-Transition Decision Analysis Model

By Garin Margaret C.  

Clinical Drug Investigation, Vol. 29, Iss. 10, 2009-10 ,pp. : 635-646

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine: A Markov Model Application

By Yu Junhua  

CNS Drugs, Vol. 24, Iss. 8, 2010-08 ,pp. : 695-712

Adis International

Access to resources Recommend Favorite

Treatment of Advanced Parkinson's Disease in the United States: A Cost-Utility Model

By Groenendaal Huybert  

Clinical Drug Investigation, Vol. 30, Iss. 11, 2010-11 ,pp. : 789-798

Adis International

Access to resources Recommend Favorite